Cancer Control最新文献

{"title":"Global, Regional, and National Burden and Trends of Soft Tissue and Other Extraosseous Sarcomas From 1990 to 2021.","authors":"Rui Zhu, Ziyuan Shen, Haijuan Zhu, Jisen Zhang, Xing Xing, Shengyou Wang, Jialiu Fang","doi":"10.1177/10732748251355841","DOIUrl":"10.1177/10732748251355841","url":null,"abstract":"<p><p><b>Introduction:</b> Soft Tissue and Other Extraosseous Sarcomas (STOES) represent a rare and heterogeneous group of malignancies with significant clinical challenges due to their complexity and aggressiveness. Despite their low prevalence, the global impact of STOES is substantial, necessitating a detailed examination of their epidemiology and disease burden. <b>Methods:</b> This comprehensive analysis utilized data from the Global Health Data Exchange (GHDx) covering the years 1990 to 2021. We assessed the incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALYs) for STOES, categorized by location, sex, and socio-demographic indices. Statistical methods included Estimated Annual Percentage Change (EAPC), Spearman correlation analysis, and Bayesian age-period-cohort modeling. <b>Findings:</b> In 2021, STOES cases reached a global prevalence of 480,473, a significant increase from 1990. High Socio-Demographic Index (SDI) regions exhibited the highest age-standardized incidence and prevalence rates (ASIR and ASPR) at 2.05 and 10.61 per 100,000 population, respectively. Notably, significant increases were also observed in Central Asia, Central Europe, and Southern Sub-Saharan Africa. Males consistently showed higher disease rates than females. The decomposition analysis highlighted population growth and aging as primary drivers of the observed trends. Forecasting suggests a decline in the global STOES burden by 2030, though disparities will persist, particularly among males. <b>Conclusion:</b> The study reveals critical geographic and demographic disparities in the burden of STOES, underscoring the ongoing higher risk among males and in certain global regions. Despite projected declines in overall disease burden by 2030, substantial disparities are expected to persist, necessitating targeted public health interventions and robust policies to effectively mitigate these differences and enhance global health outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251355841"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review.","authors":"Sreelatha Akkala, Mohammed Zuber, Julie Alaere Atta, Nompumelelo O Mzizi, Jyothi Akkula","doi":"10.1177/10732748251341520","DOIUrl":"10.1177/10732748251341520","url":null,"abstract":"<p><p>BackgroundIn 2024, breast cancer is the second most common cancer globally, affecting 2.3 million women. In the United States (US), 310 720 new female breast cancer cases were estimated in 2024. Existing research has identified substantial disparities in breast cancer treatment and survival based on socioeconomic status (SES). This systematic review examines the association between the key SES indicators income, education, and occupation on breast cancer outcomes among the US breast cancer patients.MethodsAn electronic search was conducted using Medline®, Embase®, and Web of Science, from inception to December 2023. Observational studies examining the influence of SES indicators on breast cancer outcomes, including treatment receipt, adherence, and survival, were included. Data were summarized qualitatively due to heterogeneity in SES measures and outcome definitions.ResultsOf 2600 studies retrieved from the searches, 23 studies met the inclusion criteria (19 cohort, 4 cross-sectional). Women with lower SES were less likely to receive or experience delay in receiving the recommended treatment than women with higher SES. In addition, women with low household income (<$25,000) were more likely to report discontinuations in therapy as compared to women with an income of $50,000 or more. Education level influenced treatment adherence and timely care, with higher educational attainment linked to improved survival rates. Occupational status impacted treatment continuity, with low-wage jobs and inflexible work schedules contributing to delays and discontinuation of care.ConclusionSES significantly influences breast cancer care and survival, with lower SES associated with delayed treatment, poorer adherence, and worse outcomes. Healthcare interventions and policies focusing on equitable access to quality care tailored to all women, regardless of their socioeconomic background, may improve breast cancer outcomes for the patients with various demographic characteristics in the US.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341520"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cultural and Linguistic Adaptation of an Evidence-Based Tailored Navigation Intervention to Increase Cancer Screening Uptake Among Southeast Asian Women.","authors":"Jennifer Kue, Judith A Tate, Bárbara Piñeiro, Laura A Szalacha, Bounthanh Phommasathit, Somany Pich, Usha Menon","doi":"10.1177/10732748251329867","DOIUrl":"10.1177/10732748251329867","url":null,"abstract":"<p><p>BackgroundSoutheast Asian immigrant women in the U.S. have high rates of breast and cervical cancer, yet they are the least likely of all racial/ethnic groups to get screened. To address this disparity, we adapted the evidence-based Tailored Intervention Messaging System^© (TIMS^©), which uses tailored messages and navigation by culturally and linguistically matched community health advisors to overcome barriers to cancer screening.ObjectivesThis study describes the cultural and linguistic adaptation of TIMS^© to improve breast and cervical cancer screening among Southeast Asian immigrant women in the U.S.MethodsGuided by Stirman et al.'s adaptation framework, we conducted focus groups and in-depth interviews to identify key constructs related to cancer screening (knowledge, perceived barriers, perceived risk, benefits, self-efficacy). Using the TIMS^© and the thematic content from qualitative data, we modified messages for content and context. Messages were divided into three categories: 1) existing messages identified in thematic analyses, 2) existing messages not identified in thematic analyses, and 3) new messages that emerged from thematic analyses.ResultsContextual and content modifications were made to the TIMS^© message library. Messages were translated into Lao, Khmer, and Vietnamese. Through an iterative process, the investigator, community health advisors, and cultural community advisory board members reviewed and revised the messages for translation accuracy, relevance, and clarity.ConclusionUsing relatable language and context is critical to engaging women from Southeast Asian communities in improving breast and cervical cancer screening uptake. This adaptation approach can be applied to tailor interventions for other languages, cultures, and underrepresented groups.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251329867"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Acceptability of an App-Based, Multimodal Prehabilitation Program for Women Undergoing Surgery for Gynaecological Cancer.","authors":"Chhaya Ganda-Heath, Anke Smits, Christine Ang, Nithya Ratnavelu","doi":"10.1177/10732748251375516","DOIUrl":"10.1177/10732748251375516","url":null,"abstract":"<p><p>IntroductionPrehabilitation aims to optimise functional capacity, nutritional status, and mental wellbeing, to minimise surgical morbidity and enhance recovery. Hospital-based prehabilitation programs may face practical barriers, such as distance, time, and cost of travel. App-based prehabilitation may therefore offer a practical solution.ObjectiveThe aim of this study was to assess the feasibility, acceptability, and safety of introducing an app-based prehabilitation program into the standard care for women undergoing gynaecological cancer surgery.MethodsThis was a feasibility study performed as part of a prehabilitation service development project for women undergoing gynaecological cancer surgery between April 2024 and May 2024. Women were approached to trial the 'Surgery Hero' prehabilitation app prior to surgery, which was a multimodal app-based intervention including physical exercise, nutrition, and mental wellbeing through information modules, videos, and real-time access to a health coach. Feasibility was assessed through recruitment, activation, participation, and drop-out rates, and adverse events were monitored. Acceptability was assessed through participant satisfaction scores, and semi-structured interviews with thematic analysis of facilitators and barriers to program participation.ResultsFifteen licenses were available and successfully utilised, with a recruitment rate of 58.6% and an activation rate of 88.2%. The participation rate was 93.3% and the mean engagement rate was 76.3%. No adverse events were reported. The mean overall program satisfaction score was 4.5 out of 5. Participants felt motivated to participate and were reassured by the coaching calls and information provision. However, they felt limited by the short preoperative interval and their current state of health.ConclusionsApp-based prehabilitation appears to be a feasible, acceptable, and safe option for women undergoing surgery for a gynaecological cancer. However, further studies are needed to confirm these findings.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251375516"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Management in BRCA Carriers with Early Breast Cancer.","authors":"Bruno Muñante, Roberto Paz-Manrique, Joseph A Pinto, Henry L Gomez","doi":"10.1177/10732748251377864","DOIUrl":"10.1177/10732748251377864","url":null,"abstract":"<p><p>BackgroundBreast cancer remains a leading cause of cancer-related morbidity and mortality globally, with BRCA1/2 mutation carriers facing distinct challenges due to aggressive tumor biology and heightened risks of contralateral and secondary cancers.PurposeThis review synthesizes evidence on managing early-stage breast cancer in BRCA mutation carriers, emphasizing Latin America's heterogeneous BRCA prevalence (ranging from 5% to 25.7% across countries), which underscores the need for region-specific genetic screening. BRCA-associated tumors exhibit homologous recombination deficiency, informing therapeutic strategies such as PARP inhibitors, which exploit synthetic lethality, as demonstrated by the OlympiA trial showing Olaparib's sustained survival benefits (28% reduction in mortality risk). Imaging strategies must adapt to BRCA-related tumor phenotypes: BRCA1 carriers often present mammography-elusive tumors, favoring MRI, while abbreviated MRI protocols offer cost-effective alternatives without compromising sensitivity. Surgical decision-making balances breast-conserving surgery (BCS) and mastectomy, with studies showing comparable survival outcomes but elevated contralateral cancer risk post-BCS (10-year risk: 14%), necessitating vigilant surveillance. Contralateral prophylactic mastectomy reduces contralateral cancer risk but requires personalized risk-benefit discussions. Neoadjuvant platinum-based chemotherapy shows higher pathologic complete response rates in BRCA carriers, particularly in triple-negative subtypes, though adjuvant platinum benefits remain under investigation. Emerging immunotherapies, such as pembrolizumab in KEYNOTE-522, show promise but lack BRCA-specific efficacy data. Special considerations for transgender BRCA carriers highlight evolving screening guidelines, including mammography for hormonally treated transgender women and multimodal imaging for non-mastectomized transgender men. ConclusionsOptimizing outcomes for BRCA mutation carriers demands multidisciplinary, personalized approaches integrating genetic, regional, and clinical factors. Advances in targeted therapies, refined imaging, and risk-adapted surgery emphasize the importance of shared decision-making and ongoing research to address knowledge gaps in survivorship and equitable care.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251377864"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Handgrip Strength in Lung Cancer: Findings From a Multicenter Prospective Cohort Study.","authors":"Xin Wang, Hong Zhao, Lu Liang, Ying Gao, Lei Song, Hanping Shi","doi":"10.1177/10732748251375518","DOIUrl":"10.1177/10732748251375518","url":null,"abstract":"<p><p>BackgroundHandgrip strength (HGS), a simple and practical indicator of skeletal muscle function, has emerged as a potential prognostic marker, yet its predictive value in lung cancer remains to be fully elucidated. This study aimed to evaluate the prognostic significance of HGS for Overall Survival (OS) in patients with lung cancer, and to develop a prognostic model integrating HGS and hematologic parameters.MethodsThis prospective cohort study was based on the Investigation on Nutrition Status and its Clinical Outcome of Common Cancers (INSCOC). A total of 3604 pathologically confirmed lung cancer patients were included. Demographic, clinical, and nutrition-related data were collected. The association between HGS and OS was assessed using Cox proportional hazards models. A nomogram was developed, and its predictive performance was evaluated using receiver operating characteristic (ROC) curves and the concordance index (C-index).ResultsHGS was significantly associated with OS in patients with lung cancer. Compared with the lowest quartile (Q1), patients in Q2, Q3, and Q4 showed 23.9% (HR = 0.761, 95% CI: 0.666-0.869, <i>P</i> < 0.001), 21.3% (HR = 0.787, 95%CI: 0.684-0.907, <i>P</i> = 0.001), and 41.1% (HR = 0.589, 95% CI: 0.506-0.686, <i>P</i> < 0.001) reductions in mortality risk, respectively. In multivariate analysis, sex, HGS, and hemoglobin were identified as independent protective factors, while elevated serum glucose and platelet count were independent risk factors for poor prognosis. The nomogram model constructed based on these variables yielded area under the curve (AUC) values of 64.2%, 61.3%, and 59.8% for predicting 1-, 2-, and 3-year OS, respectively, with a C-index of 0.607 (95% CI: 0.593-0.621), outperforming HGS alone (C-index = 0.541) or any single hematological parameter.ConclusionsHGS is an independent predictor of survival in lung cancer. Combining HGS with hematologic indicators enhances prognostic accuracy. The developed nomogram may serve as a practical tool for individualized prognostication and nutrition-based interventions.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251375518"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment.","authors":"Sourio Chakraborty, Udit Basak, Sumon Mukherjee, Sumoyee Mukherjee, Tanya Das","doi":"10.1177/10732748251381441","DOIUrl":"10.1177/10732748251381441","url":null,"abstract":"<p><p>Success of cancer immunotherapy (CIT) is intricately influenced by the tumor microenvironment (TME), a complex ecosystem that encompasses immune cells, stromal elements, and extracellular components. Despite the clinical breakthroughs of immune-checkpoint inhibitors (ICIs), adoptive cell therapies, cancer vaccines, and other immunotherapeutic interventions, many patients fail to respond and eventually die. Emerging evidence points to cancer stem cells (CSCs) as critical drivers of immune evasion, therapy-resistance, and tumor relapse. CSCs modulate the TME by secreting immune-suppressive factors, recruiting regulatory immune cells, and inducing phenotype-switching of anti-tumor TME subsets, thereby creating a protective niche that hinders immune surveillance. Conversely, the TME protects CSCs through hypoxia, altered metabolism, and immuno-suppressive cell populations. This bi-directional crosstalk supports tumor progression and provides resistance to immunotherapeutic strategies mainly by: (i) escaping immune-recognition and inhibiting active T cells <i>via</i> high immune-checkpoint molecule expression, (ii) creating immunosuppressive pro-tumor environment, and (iii) evading immune-mediated apoptosis of CSCs along with therapy-induced enrichment of their pool. Targeting CSCs in concert with reprogramming the TME <i>via</i> CSC-directed agents, metabolic modulators, or combinatorial immunotherapies, therefore, offers a promising avenue to overcome immunotherapy-resistance and achieve durable clinical responses. This review discusses the deeper mechanistic understanding of CSC-TME interactions, in light of designing next-generation immunotherapies with broader efficacy across diverse tumor types.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251381441"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses.","authors":"S M Shahriar Alam, Mashiat Tasnim, Tasbir Amin, S M Bakhtiar Ul Islam","doi":"10.1177/10732748251382295","DOIUrl":"10.1177/10732748251382295","url":null,"abstract":"<p><p>When considering treatment-related side effects, cancer therapies often present the most significant severity. Given considerations of safety and efficacy, there is a growing inclination towards biological therapeutic approaches, with Oncolytic Viruses (OVs) emerging as a prominent focus. Initial investigations into OVs commenced with Adenovirus, subsequently leading to the study of other viruses, including Herpes Simplex Virus (HSV), Reovirus, and measles virus, evaluating their potential safety profiles and antitumor efficacy in human subjects. The fundamental principle underlying OV-based cancer therapy lies in harnessing viral infectivity and immunogenicity, which are engineered for selective targeting of tumor cells. Following the US Food and Drug Administration (FDA) approval of the HSV-based therapy (T-VEC) for Melanoma, interest in exploring other viral platforms for the potential treatment of various cancer types has notably expanded. A considerable number of OVs have progressed to various stages of clinical evaluation. This review provides an in-depth examination of OV classification, mechanisms of action, delivery strategies, and crucial genetic modifications, furthermore summarizing data from pivotal trials to underscore the efficacy and advancement of OVs from investigational modalities to clinical implementation. For the scope of this review, clinical trial data spanning the past 11 years (2013 to 2024) were accessed from ClinicalTrials.gov and further categorized according to their ongoing clinical trial phases and their utilization in combination with Immune Checkpoint Inhibitors (ICI) or other established therapies. In summary, this work presents a comprehensive overview of recent developments within the field of cancer therapy, specifically concerning Oncolytic Viruses.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251382295"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.","authors":"Haibo Wang, Tao Lu, Xinlong Zheng, Kan Jiang, Longfeng Zhang, Xiaobin Zheng, Qian Miao, Shiwen Wu, Zihua Zou, Shanshan Yang, Yujing Li, Sihui Chen, Yiquan Xu, Gen Lin","doi":"10.1177/10732748241311223","DOIUrl":"10.1177/10732748241311223","url":null,"abstract":"<p><strong>Background: </strong>The proportion and impact of minimal pleural effusion (PE) on prognosis remain blurred in operable non-small cell lung cancer (NSCLC) patients who reported minimal PE on imaging.</p><p><strong>Methods: </strong>Clinical and prognostic data of operable NSCLC patients who presented no distant metastasis, no direct pleural invasion, but minimal PE on preoperative imaging were retrospectively analyzed. The patients were divided into surgical (81 cases) and non-surgical (10 cases) cohorts. Potential or suspected malignant PE or pleural metastases were confirmed by surgery. The overall survival (OS) was analyzed by Kaplan-Meier curve and prognostic factors by multivariate Cox regression.</p><p><strong>Results: </strong>The surgical cohort reported no pleural invasion on preoperative imaging and no pleural metastases by postoperative pathology, with an overall median disease-free survival of 36.7 (28.6, 44.7) months and a median OS of 59.8 (45.7, 73.2) months, with the latter significantly longer in the surgical cohort than in the non-surgical cohort (59.8 months vs 20.37 months, <i>P</i> < 0.001). Multivariate analysis indicated surgical treatment as an independent prognostic factor for OS.</p><p><strong>Conclusion: </strong>Malignant PE is rare in operable NSCLC patients who report the presence of minimal PE but no distant metastasis or direct pleural invasion on preoperative imaging. Surgery may be the preferred treatment for these patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241311223"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter re: Blood-Based Multi-Cancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening.","authors":"K P Ameya, Durairaj Sekar","doi":"10.1177/10732748251317688","DOIUrl":"10.1177/10732748251317688","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317688"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}